January 26, 2018 / 10:37 PM / in a month

BRIEF-Celgene Says Entered Into Settlement With Actavis​

Jan 26 (Reuters) - Celgene Corp:

* CELGENE - ENTERED INTO SETTLEMENT WITH ACTAVIS LLC TO TERMINATE PENDING PATENT LITIGATION, IPR CHALLENGES RELATING TO CERTAIN PATENTS FOR ABRAXANE​

* CELGENE - TO GIVE ACTAVIS LICENSE TO PATENTS TO MANUFACTURE, SELL GENERIC PACLITAXEL PROTEIN-BOUND PARTICLES IN U.S. FROM MARCH 31, 2022 Source text - bit.ly/2EcZicz Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below